Mavacamten + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiomyopathy, Hypertrophic
Conditions
Cardiomyopathy, Hypertrophic
Trial Timeline
Apr 17, 2024 → Mar 28, 2031
NCT ID
NCT06253221About Mavacamten + Placebo
Mavacamten + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Cardiomyopathy, Hypertrophic. The current trial status is active. This product is registered under clinical trial identifier NCT06253221. Target conditions include Cardiomyopathy, Hypertrophic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06253221 | Phase 3 | Active |
| NCT04349072 | Phase 3 | Completed |
Competing Products
20 competing products in Cardiomyopathy, Hypertrophic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib + Placebo | AMO Pharma | Phase 2 | 44 |
| Mavacamten | LianBio | Phase 1 | 25 |
| Mavacamten + Placebo | LianBio | Phase 3 | 69 |
| CT-G20 + Placebo | Celltrion | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 85 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 33 |
| AZD4063 | AstraZeneca | Phase 1 | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| candesartan | AstraZeneca | Phase 2 | 52 |
| LCZ696 + Placebo | Novartis | Phase 2 | 52 |
| Darbepoetin alfa | Amgen | Pre-clinical | 22 |
| Eleclazine + Placebo | Gilead Sciences | Phase 2/3 | 64 |
| Ranolazine | Gilead Sciences | Approved | 84 |
| Ranexa + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine | Gilead Sciences | Pre-clinical | 22 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |